Evaluation of plasma-free endocannabinoids and their congeners in abstinent cocaine addicts seeking outpatient treatment: impact of psychiatric co-morbidity

Cocaine is associated with serious health problems including psychiatric co‐morbidity. There is a need for the identification of biomarkers for the stratification of cocaine‐addicted subjects. Several studies have evaluated circulating endocannabinoid‐related lipids as biomarkers of inflammatory, me...

Full description

Saved in:
Bibliographic Details
Published inAddiction biology Vol. 18; no. 6; pp. 955 - 969
Main Authors Pavón, Francisco Javier, Araos, Pedro, Pastor, Antoni, Calado, Montserrat, Pedraz, María, Campos-Cloute, Rafael, Ruiz, Juan Jesús, Serrano, Antonia, Blanco, Eduardo, Rivera, Patricia, Suárez, Juan, Romero-Cuevas, Miguel, Pujadas, Mitona, Vergara-Moragues, Esperanza, Gornemann, Isolde, Torrens, Marta, de la Torre, Rafael, Rodríguez de Fonseca, Fernando
Format Journal Article
LanguageEnglish
Published United States Blackwell Publishing Ltd 01.11.2013
John Wiley & Sons, Inc
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Cocaine is associated with serious health problems including psychiatric co‐morbidity. There is a need for the identification of biomarkers for the stratification of cocaine‐addicted subjects. Several studies have evaluated circulating endocannabinoid‐related lipids as biomarkers of inflammatory, metabolic and mental disorders. However, little is known in substance use disorders. This study characterizes both free N‐acyl‐ethanolamines (NAEs) and 2‐acyl‐glycerols in abstinent cocaine addicts from outpatient treatment programs who were diagnosed with cocaine use disorder (CUD; n = 88), and age‐/gender‐/body mass‐matched healthy control volunteers (n = 46). Substance and mental disorders that commonly occur with substance abuse were assessed by the semi‐structured interview ‘Psychiatric Research Interview for Substance and Mental Diseases' according to the ‘Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision’ (DSM‐IV‐TR) and plasma‐free acyl derivatives were quantified by a liquid chromatography‐tandem mass spectrometry system. The results indicate that plasma acyl derivatives are altered in abstinent cocaine‐addicted subjects with CUD (CUD subjects). While NAEs were found to be increased, 2‐acyl‐glycerols were decreased in CUD subjects compared with controls. Multivariate predictive models based on these lipids as explanatory variables were developed to distinguish CUD subjects from controls providing high discriminatory power. However, these alterations were not influenced by the DSM‐IV‐TR criteria for cocaine abuse and dependence as cocaine trait severity measure. In contrast, we observed that some free acyl derivatives in CUD subjects were found to be affected by the diagnosis of some co‐morbid psychiatric disorders. Thus, we found that the monounsaturated NAEs were significantly elevated in CUD subjects diagnosed with mood [N‐oleoyl‐ethanolamine and N‐palmitoleoyl‐ethanolamine (POEA)] and anxiety (POEA) disorders compared with non‐co‐morbid CUD subjects. Interestingly, the coexistence of alcohol use disorders did not influence the circulating levels of these free acyl derivatives. In summary, we have identified plasma‐free acyl derivatives that might serve as reliable biomarkers for CUD. Furthermore, we found that monounsaturated NAE levels are also enhanced by co‐morbid mood and anxiety disorders in cocaine addicts. These findings open the way for the development of new strategies for cocaine addiction diagnosis and treatment.
AbstractList Cocaine is associated with serious health problems including psychiatric co-morbidity. There is a need for the identification of biomarkers for the stratification of cocaine-addicted subjects. Several studies have evaluated circulating endocannabinoid-related lipids as biomarkers of inflammatory, metabolic and mental disorders. However, little is known in substance use disorders. This study characterizes both free N-acyl-ethanolamines (NAEs) and 2-acyl-glycerols in abstinent cocaine addicts from outpatient treatment programs who were diagnosed with cocaine use disorder (CUD; n = 88), and age-/gender-/body mass-matched healthy control volunteers (n = 46). Substance and mental disorders that commonly occur with substance abuse were assessed by the semi-structured interview 'Psychiatric Research Interview for Substance and Mental Diseases' according to the 'Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision' (DSM-IV-TR) and plasma-free acyl derivatives were quantified by a liquid chromatography-tandem mass spectrometry system. The results indicate that plasma acyl derivatives are altered in abstinent cocaine-addicted subjects with CUD (CUD subjects). While NAEs were found to be increased, 2-acyl-glycerols were decreased in CUD subjects compared with controls. Multivariate predictive models based on these lipids as explanatory variables were developed to distinguish CUD subjects from controls providing high discriminatory power. However, these alterations were not influenced by the DSM-IV-TR criteria for cocaine abuse and dependence as cocaine trait severity measure. In contrast, we observed that some free acyl derivatives in CUD subjects were found to be affected by the diagnosis of some co-morbid psychiatric disorders. Thus, we found that the monounsaturated NAEs were significantly elevated in CUD subjects diagnosed with mood [N-oleoyl-ethanolamine and N-palmitoleoyl-ethanolamine (POEA)] and anxiety (POEA) disorders compared with non-co-morbid CUD subjects. Interestingly, the coexistence of alcohol use disorders did not influence the circulating levels of these free acyl derivatives. In summary, we have identified plasma-free acyl derivatives that might serve as reliable biomarkers for CUD. Furthermore, we found that monounsaturated NAE levels are also enhanced by co-morbid mood and anxiety disorders in cocaine addicts. These findings open the way for the development of new strategies for cocaine addiction diagnosis and treatment.Cocaine is associated with serious health problems including psychiatric co-morbidity. There is a need for the identification of biomarkers for the stratification of cocaine-addicted subjects. Several studies have evaluated circulating endocannabinoid-related lipids as biomarkers of inflammatory, metabolic and mental disorders. However, little is known in substance use disorders. This study characterizes both free N-acyl-ethanolamines (NAEs) and 2-acyl-glycerols in abstinent cocaine addicts from outpatient treatment programs who were diagnosed with cocaine use disorder (CUD; n = 88), and age-/gender-/body mass-matched healthy control volunteers (n = 46). Substance and mental disorders that commonly occur with substance abuse were assessed by the semi-structured interview 'Psychiatric Research Interview for Substance and Mental Diseases' according to the 'Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision' (DSM-IV-TR) and plasma-free acyl derivatives were quantified by a liquid chromatography-tandem mass spectrometry system. The results indicate that plasma acyl derivatives are altered in abstinent cocaine-addicted subjects with CUD (CUD subjects). While NAEs were found to be increased, 2-acyl-glycerols were decreased in CUD subjects compared with controls. Multivariate predictive models based on these lipids as explanatory variables were developed to distinguish CUD subjects from controls providing high discriminatory power. However, these alterations were not influenced by the DSM-IV-TR criteria for cocaine abuse and dependence as cocaine trait severity measure. In contrast, we observed that some free acyl derivatives in CUD subjects were found to be affected by the diagnosis of some co-morbid psychiatric disorders. Thus, we found that the monounsaturated NAEs were significantly elevated in CUD subjects diagnosed with mood [N-oleoyl-ethanolamine and N-palmitoleoyl-ethanolamine (POEA)] and anxiety (POEA) disorders compared with non-co-morbid CUD subjects. Interestingly, the coexistence of alcohol use disorders did not influence the circulating levels of these free acyl derivatives. In summary, we have identified plasma-free acyl derivatives that might serve as reliable biomarkers for CUD. Furthermore, we found that monounsaturated NAE levels are also enhanced by co-morbid mood and anxiety disorders in cocaine addicts. These findings open the way for the development of new strategies for cocaine addiction diagnosis and treatment.
Cocaine is associated with serious health problems including psychiatric co‐morbidity. There is a need for the identification of biomarkers for the stratification of cocaine‐addicted subjects. Several studies have evaluated circulating endocannabinoid‐related lipids as biomarkers of inflammatory, metabolic and mental disorders. However, little is known in substance use disorders. This study characterizes both free N‐acyl‐ethanolamines (NAEs) and 2‐acyl‐glycerols in abstinent cocaine addicts from outpatient treatment programs who were diagnosed with cocaine use disorder (CUD; n = 88), and age‐/gender‐/body mass‐matched healthy control volunteers (n = 46). Substance and mental disorders that commonly occur with substance abuse were assessed by the semi‐structured interview ‘Psychiatric Research Interview for Substance and Mental Diseases' according to the ‘Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision’ (DSM‐IV‐TR) and plasma‐free acyl derivatives were quantified by a liquid chromatography‐tandem mass spectrometry system. The results indicate that plasma acyl derivatives are altered in abstinent cocaine‐addicted subjects with CUD (CUD subjects). While NAEs were found to be increased, 2‐acyl‐glycerols were decreased in CUD subjects compared with controls. Multivariate predictive models based on these lipids as explanatory variables were developed to distinguish CUD subjects from controls providing high discriminatory power. However, these alterations were not influenced by the DSM‐IV‐TR criteria for cocaine abuse and dependence as cocaine trait severity measure. In contrast, we observed that some free acyl derivatives in CUD subjects were found to be affected by the diagnosis of some co‐morbid psychiatric disorders. Thus, we found that the monounsaturated NAEs were significantly elevated in CUD subjects diagnosed with mood [N‐oleoyl‐ethanolamine and N‐palmitoleoyl‐ethanolamine (POEA)] and anxiety (POEA) disorders compared with non‐co‐morbid CUD subjects. Interestingly, the coexistence of alcohol use disorders did not influence the circulating levels of these free acyl derivatives. In summary, we have identified plasma‐free acyl derivatives that might serve as reliable biomarkers for CUD. Furthermore, we found that monounsaturated NAE levels are also enhanced by co‐morbid mood and anxiety disorders in cocaine addicts. These findings open the way for the development of new strategies for cocaine addiction diagnosis and treatment.
Cocaine is associated with serious health problems including psychiatric co-morbidity. There is a need for the identification of biomarkers for the stratification of cocaine-addicted subjects. Several studies have evaluated circulating endocannabinoid-related lipids as biomarkers of inflammatory, metabolic and mental disorders. However, little is known in substance use disorders. This study characterizes both free N-acyl-ethanolamines (NAEs) and 2-acyl-glycerols in abstinent cocaine addicts from outpatient treatment programs who were diagnosed with cocaine use disorder (CUD; n=88), and age-/gender-/body mass-matched healthy control volunteers (n=46). Substance and mental disorders that commonly occur with substance abuse were assessed by the semi-structured interview 'Psychiatric Research Interview for Substance and Mental Diseases' according to the 'Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision' (DSM-IV-TR) and plasma-free acyl derivatives were quantified by a liquid chromatography-tandem mass spectrometry system. The results indicate that plasma acyl derivatives are altered in abstinent cocaine-addicted subjects with CUD (CUD subjects). While NAEs were found to be increased, 2-acyl-glycerols were decreased in CUD subjects compared with controls. Multivariate predictive models based on these lipids as explanatory variables were developed to distinguish CUD subjects from controls providing high discriminatory power. However, these alterations were not influenced by the DSM-IV-TR criteria for cocaine abuse and dependence as cocaine trait severity measure. In contrast, we observed that some free acyl derivatives in CUD subjects were found to be affected by the diagnosis of some co-morbid psychiatric disorders. Thus, we found that the monounsaturated NAEs were significantly elevated in CUD subjects diagnosed with mood [N-oleoyl-ethanolamine and N-palmitoleoyl-ethanolamine (POEA)] and anxiety (POEA) disorders compared with non-co-morbid CUD subjects. Interestingly, the coexistence of alcohol use disorders did not influence the circulating levels of these free acyl derivatives. In summary, we have identified plasma-free acyl derivatives that might serve as reliable biomarkers for CUD. Furthermore, we found that monounsaturated NAE levels are also enhanced by co-morbid mood and anxiety disorders in cocaine addicts. These findings open the way for the development of new strategies for cocaine addiction diagnosis and treatment. [PUBLICATION ABSTRACT]
Author Campos-Cloute, Rafael
Torrens, Marta
Blanco, Eduardo
Vergara-Moragues, Esperanza
Romero-Cuevas, Miguel
Pedraz, María
Pastor, Antoni
Rivera, Patricia
Serrano, Antonia
Ruiz, Juan Jesús
Gornemann, Isolde
Araos, Pedro
Pavón, Francisco Javier
Suárez, Juan
Rodríguez de Fonseca, Fernando
Pujadas, Mitona
Calado, Montserrat
de la Torre, Rafael
Author_xml – sequence: 1
  givenname: Francisco Javier
  surname: Pavón
  fullname: Pavón, Francisco Javier
  organization: Unidad de Gestión Clínica de Salud Mental, Instituto de Investigación Biomédica de Málaga (IBIMA), Hospital Regional Universitario de Málaga, Spain
– sequence: 2
  givenname: Pedro
  surname: Araos
  fullname: Araos, Pedro
  organization: Unidad de Gestión Clínica de Salud Mental, Instituto de Investigación Biomédica de Málaga (IBIMA), Hospital Regional Universitario de Málaga, Spain
– sequence: 3
  givenname: Antoni
  surname: Pastor
  fullname: Pastor, Antoni
  organization: Neurosciences Programme, Institut Hospital del Mar d'Investigacions Mediques (IMIM), Spain
– sequence: 4
  givenname: Montserrat
  surname: Calado
  fullname: Calado, Montserrat
  organization: Unidad de Gestión Clínica de Salud Mental, Instituto de Investigación Biomédica de Málaga (IBIMA), Hospital Regional Universitario de Málaga, Spain
– sequence: 5
  givenname: María
  surname: Pedraz
  fullname: Pedraz, María
  organization: Unidad de Gestión Clínica de Salud Mental, Instituto de Investigación Biomédica de Málaga (IBIMA), Hospital Regional Universitario de Málaga, Spain
– sequence: 6
  givenname: Rafael
  surname: Campos-Cloute
  fullname: Campos-Cloute, Rafael
  organization: Centro Comarcal de Drogodependencias, Spain
– sequence: 7
  givenname: Juan Jesús
  surname: Ruiz
  fullname: Ruiz, Juan Jesús
  organization: Centro De Tratamiento Ambulatorio, Spain
– sequence: 8
  givenname: Antonia
  surname: Serrano
  fullname: Serrano, Antonia
  organization: Unidad de Gestión Clínica de Salud Mental, Instituto de Investigación Biomédica de Málaga (IBIMA), Hospital Regional Universitario de Málaga, Spain
– sequence: 9
  givenname: Eduardo
  surname: Blanco
  fullname: Blanco, Eduardo
  organization: Unidad de Gestión Clínica de Salud Mental, Instituto de Investigación Biomédica de Málaga (IBIMA), Hospital Regional Universitario de Málaga, Spain
– sequence: 10
  givenname: Patricia
  surname: Rivera
  fullname: Rivera, Patricia
  organization: Unidad de Gestión Clínica de Salud Mental, Instituto de Investigación Biomédica de Málaga (IBIMA), Hospital Regional Universitario de Málaga, Spain
– sequence: 11
  givenname: Juan
  surname: Suárez
  fullname: Suárez, Juan
  organization: Unidad de Gestión Clínica de Salud Mental, Instituto de Investigación Biomédica de Málaga (IBIMA), Hospital Regional Universitario de Málaga, Spain
– sequence: 12
  givenname: Miguel
  surname: Romero-Cuevas
  fullname: Romero-Cuevas, Miguel
  organization: Unidad de Gestión Clínica de Salud Mental, Instituto de Investigación Biomédica de Málaga (IBIMA), Hospital Regional Universitario de Málaga, Spain
– sequence: 13
  givenname: Mitona
  surname: Pujadas
  fullname: Pujadas, Mitona
  organization: Neurosciences Programme, Institut Hospital del Mar d'Investigacions Mediques (IMIM), Spain
– sequence: 14
  givenname: Esperanza
  surname: Vergara-Moragues
  fullname: Vergara-Moragues, Esperanza
  organization: Grupo de Investigación de Neuropsicología y Psiconeuroinmunología Clínica, Universidad de Granada, Spain
– sequence: 15
  givenname: Isolde
  surname: Gornemann
  fullname: Gornemann, Isolde
  organization: Unidad de Gestión Clínica de Salud Mental, Instituto de Investigación Biomédica de Málaga (IBIMA), Hospital Regional Universitario de Málaga, Spain
– sequence: 16
  givenname: Marta
  surname: Torrens
  fullname: Torrens, Marta
  organization: Neurosciences Programme, Institut Hospital del Mar d'Investigacions Mediques (IMIM), Spain
– sequence: 17
  givenname: Rafael
  surname: de la Torre
  fullname: de la Torre, Rafael
  organization: Neurosciences Programme, Institut Hospital del Mar d'Investigacions Mediques (IMIM), Spain
– sequence: 18
  givenname: Fernando
  surname: Rodríguez de Fonseca
  fullname: Rodríguez de Fonseca, Fernando
  email: fernando.rodriguez@fundacionimabis.org
  organization: Unidad de Gestión Clínica de Salud Mental, Instituto de Investigación Biomédica de Málaga (IBIMA), Hospital Regional Universitario de Málaga, Spain
BackLink https://www.ncbi.nlm.nih.gov/pubmed/24283982$$D View this record in MEDLINE/PubMed
BookMark eNqNkc9u1DAQxi1URNuFAy-ALHHhktaO43iXW7u0BVQBlUA9WhNn0rpN7GA7tPsuPCzeP_TACV_8yf7NN5r5Dsme8w4Jec3ZEc_nGNrmiJecqWfkgIt6UfCasb21lrKoSy73yWGMd4zxUknxguyXVTkXi3l5QH6f_YJ-gmS9o76jYw9xgKILiBRd6w04B4113raRgmtpukUbqPHuBh2GSK2j0MRkHbqUnw1kRaFtrUmRRsR7626on9KYW6yRFBDSkNV7aocRTNp0jStzayEFa7JHMfjQ2Nam1UvyvIM-4qvdPSM_zs--Lz8Wl18vPi1PLgsrJFOF4BKAmdrIPDxy4EKh6CpUHZetRDlnvFGLhWJ1BgyqEk1TNV1tADjHiokZebf1HYP_OWFMerDRYN-DQz9FzatFWVfV_L_QulR55XnPM_L2H_TOT8HlQdbUvFY7wzc7amoGbPUY7ABhpf9GlIHjLfBge1w9_XOm19nrnL3eZK9PPpxuRK4othU2Jnx8qoBwr2sllNTXXy708uqzOP_Gr_S1-AMOgLO0
ContentType Journal Article
Copyright 2013 Society for the Study of Addiction
2013 Society for the Study of Addiction.
Copyright_xml – notice: 2013 Society for the Study of Addiction
– notice: 2013 Society for the Study of Addiction.
DBID BSCLL
CGR
CUY
CVF
ECM
EIF
NPM
7QG
7T5
7TM
H94
7X8
7TK
DOI 10.1111/adb.12107
DatabaseName Istex
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
Animal Behavior Abstracts
Immunology Abstracts
Nucleic Acids Abstracts
AIDS and Cancer Research Abstracts
MEDLINE - Academic
Neurosciences Abstracts
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
AIDS and Cancer Research Abstracts
Immunology Abstracts
Animal Behavior Abstracts
Nucleic Acids Abstracts
MEDLINE - Academic
Neurosciences Abstracts
DatabaseTitleList MEDLINE - Academic

MEDLINE
Neurosciences Abstracts
AIDS and Cancer Research Abstracts
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Social Welfare & Social Work
EISSN 1369-1600
EndPage 969
ExternalDocumentID 3158447151
24283982
ADB12107
ark_67375_WNG_CQJ3FP1Q_W
Genre article
Research Support, Non-U.S. Gov't
Journal Article
GrantInformation_xml – fundername: Plan Nacional sobre Drogas
  funderid: 049/2009
– fundername: Consejería de Economía, Innovación y Ciencia, Junta de Andalucía UE‐FEDER
  funderid: CTS‐433
– fundername: Consejería de Salud, Junta de Andalucía
  funderid: SAS 111224
– fundername: Instituto de Salud Carlos III, Red de Trastornos Adictivos UE‐FEDER 2006 and 2012
  funderid: RD06/0001/0000; RD12/0028/0001; RD06/0001/1009; RD12/0028/0009
GroupedDBID ---
.3N
.GA
.Y3
05W
0R~
1OB
1OC
23M
24P
31~
33P
36B
3SF
3V.
4.4
50Y
50Z
52M
52O
52T
52U
52V
52W
53G
5GY
5HH
5RE
5VS
702
7PT
7X7
8-0
8-1
8-3
8-4
8-5
88E
8FE
8FH
8FI
8FJ
930
A01
A03
AAESR
AAEVG
AAHHS
AANLZ
AAONW
AASGY
AAWTL
AAXRX
AAZKR
ABCUV
ABDBF
ABIVO
ABPVW
ABUWG
ABXGK
ACAHQ
ACBWZ
ACCFJ
ACCZN
ACGEJ
ACGFS
ACGOF
ACMXC
ACPOU
ACPRK
ACXBN
ACXQS
ADBBV
ADBTR
ADEOM
ADIZJ
ADKYN
ADMGS
ADOZA
ADPDF
ADXAS
ADXPE
ADZMN
ADZOD
AEEZP
AEIGN
AEIMD
AENEX
AEQDE
AEUQT
AEUYR
AFBPY
AFGKR
AFKRA
AFPWT
AHEFC
AIACR
AIURR
AIWBW
AJBDE
AJWEG
ALAGY
ALIPV
ALMA_UNASSIGNED_HOLDINGS
ALUQN
AMBMR
AMYDB
ASPBG
ATUGU
AVWKF
AZBYB
AZFZN
AZQEC
AZVAB
BAFTC
BBNVY
BDRZF
BENPR
BFHJK
BHBCM
BHPHI
BMXJE
BPHCQ
BROTX
BRXPI
BSCLL
BVXVI
C45
CAG
CCPQU
COF
CS3
D-6
D-7
D-E
D-F
DC6
DCZOG
DPXWK
DRFUL
DRMAN
DRSTM
DUUFO
DWQXO
EAD
EAP
EAS
EBD
EBS
EJD
EMB
EMK
EMOBN
EPT
ESX
F00
F01
F04
F21
F5P
FEDTE
FUBAC
FYUFA
FZ0
G-S
G.N
GNUQQ
GODZA
H.X
HCIFZ
HF~
HMCUK
HVGLF
HZ~
KBYEO
LATKE
LEEKS
LH4
LITHE
LK8
LOXES
LP6
LP7
LUTES
LW6
LYRES
M1P
M2M
M7P
MEWTI
MK4
MRFUL
MRMAN
MRSTM
MSFUL
MSMAN
MSSTM
MXFUL
MXMAN
MXSTM
N04
N05
NF~
O66
O9-
OIG
OVD
OVEED
P2P
P2W
P2X
P2Z
P4B
P4D
PALCI
PQQKQ
PROAC
PSQYO
PSYQQ
Q.N
QB0
Q~Q
R.K
RIWAO
RJQFR
ROL
RPM
RX1
SAMSI
SUPJJ
SV3
TEORI
TUS
UB1
UKHRP
W8V
W99
WBKPD
WIH
WIJ
WIK
WNSPC
WOHZO
WUP
WXSBR
WYISQ
ZZTAW
~IA
~WT
AAFWJ
AAMMB
AANHP
AAYCA
ACCMX
ACRPL
ACUHS
ACYXJ
ADNMO
AEFGJ
AFPKN
AFWVQ
AGQPQ
AGXDD
AIDQK
AIDYY
GROUPED_DOAJ
PHGZM
PHGZT
PJZUB
PPXIY
PQGLB
CGR
CUY
CVF
ECM
EIF
NPM
7QG
7T5
7TM
H94
7X8
7TK
ID FETCH-LOGICAL-i3507-315aa0c6c5136e1a137e3f4e7f15d5e5801b799706513ce72ecb4bf6caa11e403
ISSN 1355-6215
1369-1600
IngestDate Fri Jul 11 09:29:50 EDT 2025
Thu Jul 10 22:19:16 EDT 2025
Fri Jul 25 12:06:46 EDT 2025
Mon Jul 21 05:55:45 EDT 2025
Wed Aug 20 07:27:58 EDT 2025
Wed Oct 30 09:52:38 EDT 2024
IsPeerReviewed true
IsScholarly true
Issue 6
Keywords endocannabinoid
dependence
DSM-IV-TR
psychiatric co-morbidity
Abuse
cocaine
Language English
License 2013 Society for the Study of Addiction.
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-i3507-315aa0c6c5136e1a137e3f4e7f15d5e5801b799706513ce72ecb4bf6caa11e403
Notes istex:8A0688B5B390DBF5EF8C8D0F6709F5436F18D2E4
ArticleID:ADB12107
Consejería de Economía, Innovación y Ciencia, Junta de Andalucía UE-FEDER - No. CTS-433
Consejería de Salud, Junta de Andalucía - No. SAS 111224
Figure S1 Correlation analyses between plasma levels of NAEs and 2-acyl-glycerols, and DSM-IV criteria for cocaine abuse and dependence in CUD-subjects Figure S2 Plasma levels of NAEs and 2-acyl-glycerols in CUD-subjects with comorbid alcohol use disorders Table S1 Binary logistic regression models for distinguishing cocaine use disorders (CUD) with the plasma concentrations of NAEs and polyunsaturated 2-acyl-glycerols
Instituto de Salud Carlos III, Red de Trastornos Adictivos UE-FEDER 2006 and 2012 - No. RD06/0001/0000; No. RD12/0028/0001; No. RD06/0001/1009; No. RD12/0028/0009
ark:/67375/WNG-CQJ3FP1Q-W
Plan Nacional sobre Drogas - No. 049/2009
ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 14
ObjectType-Article-1
ObjectType-Feature-2
content type line 23
PMID 24283982
PQID 1468674840
PQPubID 2028711
PageCount 15
ParticipantIDs proquest_miscellaneous_1492644840
proquest_miscellaneous_1462762175
proquest_journals_1468674840
pubmed_primary_24283982
wiley_primary_10_1111_adb_12107_ADB12107
istex_primary_ark_67375_WNG_CQJ3FP1Q_W
PublicationCentury 2000
PublicationDate 2013-11
November 2013
2013-Nov
20131101
PublicationDateYYYYMMDD 2013-11-01
PublicationDate_xml – month: 11
  year: 2013
  text: 2013-11
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
– name: Leeds
PublicationTitle Addiction biology
PublicationTitleAlternate Addiction Biology
PublicationYear 2013
Publisher Blackwell Publishing Ltd
John Wiley & Sons, Inc
Publisher_xml – name: Blackwell Publishing Ltd
– name: John Wiley & Sons, Inc
References Hasin DS, Fenton MC, Beseler C, Park JY, Wall MM (2012) Analyses related to the development of DSM-5 criteria for substance use related disorders: 2. Proposed DSM-5 criteria for alcohol, cannabis, cocaine and heroin disorders in 663 substance abuse patients. Drug Alcohol Depend 122:28-37.
LoVerme J, La Rana G, Russo R, Calignano A, Piomelli D (2005) The search for the palmitoylethanolamide receptor. Life Sci 77:1685-1698.
Siegmund SV (2010) Role of the endocannabinoid system in alcoholic liver disease. Dig Dis 28:751-755.
Razzouk D, Bordin IA, Jorge MR (2000) Comorbidity and global functioning (DSM-III-R Axis V) in a Brazilian sample of cocaine users. Subst Use Misuse 35:1307-1315.
Wiskerke J, Pattij T, Schoffelmeer AN, De Vries TJ (2008) The role of CB1 receptors in psychostimulant addiction. Addict Biol 13:225-238.
Editorial team (2010) The EMCDDA annual report 2010: the state of the drugs problem in Europe. Euro Surveill 15:19714.
Matias I, Gatta-Cherifi B, Tabarin A, Clark S, Leste-Lasserre T, Marsicano G, Piazza PV, Cota D (2012) Endocannabinoids measurement in human saliva as potential biomarker of obesity. PLoS ONE 7:e42399.
Mangieri RA, Hong KI, Piomelli D, Sinha R (2009) An endocannabinoid signal associated with desire for alcohol is suppressed in recently abstinent alcoholics. Psychopharmacology (Berl) 205:63-72.
Ferrer B, Bermudez-Silva FJ, Bilbao A, Alvarez-Jaimes L, Sanchez-Vera I, Giuffrida A, Serrano A, Baixeras E, Khaturia S, Navarro M, Parsons LH, Piomelli D, Rodriguez de Fonseca F (2007) Regulation of brain anandamide by acute administration of ethanol. Biochem J 404:97-104.
Potvin S, Kouassi E, Lipp O, Bouchard RH, Roy MA, Demers MF, Gendron A, Astarita G, Piomelli D, Stip E (2008) Endogenous cannabinoids in patients with schizophrenia and substance use disorder during quetiapine therapy. J Psychopharmacol 22:262-269.
Riddle EL, Fleckenstein AE, Hanson GR (2005) Role of monoamine transporters in mediating psychostimulant effects. AAPS J 7:E847-E851.
Torrens M, Serrano D, Astals M, Perez-Dominguez G, Martin-Santos R (2004) Diagnosing comorbid psychiatric disorders in substance abusers: validity of the Spanish versions of the Psychiatric Research Interview for Substance and Mental Disorders and the Structured Clinical Interview for DSM-IV. Am J Psychiatry 161:1231-1237.
Gonzalez S, Cascio MG, Fernandez-Ruiz J, Fezza F, Di Marzo V, Ramos JA (2002) Changes in endocannabinoid contents in the brain of rats chronically exposed to nicotine, ethanol or cocaine. Brain Res 954:73-81.
Sipe JC, Scott TM, Murray S, Harismendy O, Simon GM, Cravatt BF, Waalen J (2010) Biomarkers of endocannabinoid system activation in severe obesity. PLoS ONE 5:e8792.
Vergara-Moragues E, Gonzalez-Saiz F, Lozano OM, Betanzos Espinosa P, Fernandez Calderon F, Bilbao-Acebos I, Perez Garcia M, Verdejo Garcia A (2012) Psychiatric comorbidity in cocaine users treated in therapeutic community: substance-induced versus independent disorders. Psychiatry Res 200:734-741.
Jean-Gilles L, Feng S, Tench CR, Chapman V, Kendall DA, Barrett DA, Constantinescu CS (2009) Plasma endocannabinoid levels in multiple sclerosis. J Neurol Sci 287:212-215.
Ben-Shahar O, Sacramento AD, Miller BW, Webb SM, Wroten MG, Silva HE, Caruana AL, Gordon EJ, Ploense KL, Ditzhazy J, Kippin TE, Szumlinski KK (2013) Deficits in ventromedial prefrontal cortex group 1 metabotropic glutamate receptor function mediate resistance to extinction during protracted withdrawal from an extensive history of cocaine self-administration. J Neurosci 33:495-506a.
Schmid HH, Berdyshev EV (2002) Cannabinoid receptor-inactive N-acylethanolamines and other fatty acid amides: metabolism and function. Prostaglandins Leukot Essent Fatty Acids 66:363-376.
Fernandez-Ruiz J, Hernandez M, Ramos JA (2010) Cannabinoid-dopamine interaction in the pathophysiology and treatment of CNS disorders. CNS Neurosci Ther 16:e72-e91.
Feuerecker M, Hauer D, Gresset T, Lassas S, Kaufmann I, Vogeser M, Briegel J, Hornuss C, Chouker A, Schelling G (2012) Effect of an acute consumption of a moderate amount of ethanol on plasma endocannabinoid levels in humans. Alcohol Alcohol 47:226-232.
Desfosses J, Stip E, Bentaleb LA, Lipp O, Chiasson JP, Furtos A, Venne K, Kouassi E, Potvin S (2012) Plasma endocannabinoid alterations in individuals with substance use disorder are dependent on the 'mirror effect' of schizophrenia. Front Psychiatry 3:85.
Syed SK, Bui HH, Beavers LS, Farb TB, Ficorilli J, Chesterfield AK, Kuo MS, Bokvist K, Barrett DG, Efanov AM (2012) Regulation of GPR119 receptor activity with endocannabinoid-like lipids. Am J Physiol Endocrinol Metab 303:E1469-E1478.
Morgello S, Holzer CE 3rd, Ryan E, Young C, Naseer M, Castellon SA, Frol AB, Atkinson JH, Gelman BB, Grant I, Singer EJ (2006) Interrater reliability of the Psychiatric Research Interview for Substance and Mental Disorders in an HIV-infected cohort: experience of the National NeuroAIDS Tissue Consortium. Int J Methods Psychiatr Res 15:131-138.
Hill MN, Miller GE, Ho WS, Gorzalka BB, Hillard CJ (2008) Serum endocannabinoid content is altered in females with depressive disorders: a preliminary report. Pharmacopsychiatry 41:48-53.
Quercioli A, Pataky Z, Vincenti G, Makoundou V, Di Marzo V, Montecucco F, Carballo S, Thomas A, Staub C, Steffens S, Seimbille Y, Golay A, Ratib O, Harsch E, Mach F, Schindler TH (2011) Elevated endocannabinoid plasma levels are associated with coronary circulatory dysfunction in obesity. Eur Heart J 32:1369-1378.
Monteleone P, Matias I, Martiadis V, De Petrocellis L, Maj M, Di Marzo V (2005) Blood levels of the endocannabinoid anandamide are increased in anorexia nervosa and in binge-eating disorder, but not in bulimia nervosa. Neuropsychopharmacology 30:1216-1221.
Hasin D, Samet S, Nunes E, Meydan J, Matseoane K, Waxman R (2006) Diagnosis of comorbid psychiatric disorders in substance users assessed with the Psychiatric Research Interview for Substance and Mental Disorders for DSM-IV. Am J Psychiatry 163:689-696.
Schwarz E, Whitfield P, Nahnsen S, Wang L, Major H, Leweke FM, Koethe D, Lio P, Bahn S (2011) Alterations of primary fatty acid amides in serum of patients with severe mental illness. Front Biosci (Elite Ed) 3:308-314.
Caille S, Alvarez-Jaimes L, Polis I, Stouffer DG, Parsons LH (2007) Specific alterations of extracellular endocannabinoid levels in the nucleus accumbens by ethanol, heroin, and cocaine self-administration. J Neurosci 27:3695-3702.
Di Marzo V, Deutsch DG (1998) Biochemistry of the endogenous ligands of cannabinoid receptors. Neurobiol Dis 5:386-404.
Plaza-Zabala A, Berrendero F, Suarez J, Bermudez-Silva FJ, Fernandez-Espejo E, Serrano A, Pavon FJ, Parsons LH, De Fonseca FR, Maldonado R, Robledo P (2010) Effects of the endogenous PPAR-alpha agonist, oleoylethanolamide on MDMA-induced cognitive deficits in mice. Synapse 64:379-389.
De Marchi N, De Petrocellis L, Orlando P, Daniele F, Fezza F, Di Marzo V (2003) Endocannabinoid signalling in the blood of patients with schizophrenia. Lipids Health Dis 2:5.
Schule C, Eser D, Baghai TC, Nothdurfter C, Kessler JS, Rupprecht R (2011) Neuroactive steroids in affective disorders: target for novel antidepressant or anxiolytic drugs? Neuroscience 191:55-77.
Robins LN, Wing J, Wittchen HU, Helzer JE, Babor TF, Burke J, Farmer A, Jablenski A, Pickens R, Regier DA, Sartorius N, Towle LH (1988) The Composite International Diagnostic Interview-an epidemiologic instrument suitable for use in conjunction with different diagnostic systems and in different cultures. Arch Gen Psychiatry 45:1069-1077.
Mascia P, Pistis M, Justinova Z, Panlilio LV, Luchicchi A, Lecca S, Scherma M, Fratta W, Fadda P, Barnes C, Redhi GH, Yasar S, Le Foll B, Tanda G, Piomelli D, Goldberg SR (2011) Blockade of nicotine reward and reinstatement by activation of alpha-type peroxisome proliferator-activated receptors. Biol Psychiatry 69:633-641.
Pavón FJ, Serrano A, Romero-Cuevas M, Alonso M, Rodríguez de Fonseca F (2010) Oleoylethanolamide: a new player in peripheral control of energy metabolism. Therapeutic implications. Drug Discov Today Dis Mech 7:e175-e183.
Deschaux O, Vendruscolo LF, Schlosburg JE, Diaz-Aguilar L, Yuan CJ, Sobieraj JC, George O, Koob GF, Mandyam CD (2012) Hippocampal neurogenesis protects against cocaine-primed relapse. Addict Biol. doi:10.1111/adb.12019.
Karila L, Petit A, Lowenstein W, Reynaud M (2012) Diagnosis and consequences of cocaine addiction. Curr Med Chem 19:5612-5618.
Diercks DB, Fonarow GC, Kirk JD, Jois-Bilowich P, Hollander JE, Weber JE, Wynne J, Mills RM, Yancy C, Peacock WF 4th (2008) Illicit stimulant use in a United States heart failure population presenting to the emergency department (from the Acute Decompensated Heart Failure National Registry Emergency Module). Am J Cardiol 102:1216-1219.
Herrero MJ, Domingo-Salvany A, Torrens M, Brugal MT (2008) Psychiatric comorbidity in young cocaine users: induced versus independent disorders. Addiction 103:284-293.
Kaufmann I, Schelling G, Eisner C, Richter HP, Krauseneck T, Vogeser M, Hauer D, Campolongo P, Chouker A, Beyer A, Thiel M (2008) Anandamide and neutrophil function in patients with fibromyalgia. Psychoneuroendocrinology 33:676-685.
Serrano A, Parsons LH (2011) Endocannabinoid influence in drug reinforcement, dependence and addiction-related behaviors. Pharmacol Ther 132:215-241.
Rivera P, Luque-Rojas MJ, Pastor A, Blanco E, Pavon FJ, Serrano A, Crespillo A, Vida M, Grondona JM, Cifuentes M, Bermudez-Silva FJ, de la Torre R, de Fonseca FR, Suarez J (2013a) Diet-dependent modulation of hippocampal expression of endocannabinoid signaling-related proteins in cannabinoid antagonist-treated obese rats. Eur J Neurosci 37:105-117.
Rodriguez de Fonseca F, Del Arco I, Bermudez-Silva FJ, Bilbao A, Cippitelli A, Navarro M (2005) The endocannabinoid system: physiology and pharmacology. Alcohol Alcohol 40:2-14.
Thomas MJ, Kalivas PW, Shaham Y (2008) Neuroplasticity in the mesolimbic dopamine system and cocaine addiction. Br J Pharmacol 154:327-342.
Orio
2013b; 16
2010; 16
2010; 15
2012; 122
2009; 43
2012; 200
2004; 29
2010; 224
2004; 161
2002; 954
2012; 19
2008; 33
2011; 191
2008; 103
2008; 102
1998; 353
2013; 18
2010; 64
2010; 28
2003; 2
2006; 163
2009; 287
2005; 30
1988; 45
2010; 1801
2008; 22
2013; 110
2011; 69
2010; 5
2008; 154
2005; 77
2010; 7
2007; 27
2009; 205
2007; 404
2012
2013a; 37
2006; 15
2005; 40
2011; 32
2008; 13
1999; 2
2011; 3
2012; 303
2011; 132
2012; 3
2003; 425
2013; 33
2001; 7
2000; 35
2002; 66
2005; 7
2009; 8
2008; 41
2013
2012; 47
2012; 7
1998; 5
References_xml – reference: Schmid HH, Berdyshev EV (2002) Cannabinoid receptor-inactive N-acylethanolamines and other fatty acid amides: metabolism and function. Prostaglandins Leukot Essent Fatty Acids 66:363-376.
– reference: Bilbao A, Blanco E, Luque-Rojas MJ, Suarez J, Palomino A, Vida M, Araos P, Bermudez-Silva FJ, Fernandez-Espejo E, Spanagel R, Rodriguez de Fonseca F (2013) Oleoylethanolamide dose-dependently attenuates cocaine-induced behaviours through a PPARalpha receptor-independent mechanism. Addict Biol 18:78-87.
– reference: Desfosses J, Stip E, Bentaleb LA, Lipp O, Chiasson JP, Furtos A, Venne K, Kouassi E, Potvin S (2012) Plasma endocannabinoid alterations in individuals with substance use disorder are dependent on the 'mirror effect' of schizophrenia. Front Psychiatry 3:85.
– reference: Hasin D, Samet S, Nunes E, Meydan J, Matseoane K, Waxman R (2006) Diagnosis of comorbid psychiatric disorders in substance users assessed with the Psychiatric Research Interview for Substance and Mental Disorders for DSM-IV. Am J Psychiatry 163:689-696.
– reference: Diercks DB, Fonarow GC, Kirk JD, Jois-Bilowich P, Hollander JE, Weber JE, Wynne J, Mills RM, Yancy C, Peacock WF 4th (2008) Illicit stimulant use in a United States heart failure population presenting to the emergency department (from the Acute Decompensated Heart Failure National Registry Emergency Module). Am J Cardiol 102:1216-1219.
– reference: Schule C, Eser D, Baghai TC, Nothdurfter C, Kessler JS, Rupprecht R (2011) Neuroactive steroids in affective disorders: target for novel antidepressant or anxiolytic drugs? Neuroscience 191:55-77.
– reference: Kaufmann I, Schelling G, Eisner C, Richter HP, Krauseneck T, Vogeser M, Hauer D, Campolongo P, Chouker A, Beyer A, Thiel M (2008) Anandamide and neutrophil function in patients with fibromyalgia. Psychoneuroendocrinology 33:676-685.
– reference: Monteleone P, Matias I, Martiadis V, De Petrocellis L, Maj M, Di Marzo V (2005) Blood levels of the endocannabinoid anandamide are increased in anorexia nervosa and in binge-eating disorder, but not in bulimia nervosa. Neuropsychopharmacology 30:1216-1221.
– reference: Torrens M, Serrano D, Astals M, Perez-Dominguez G, Martin-Santos R (2004) Diagnosing comorbid psychiatric disorders in substance abusers: validity of the Spanish versions of the Psychiatric Research Interview for Substance and Mental Disorders and the Structured Clinical Interview for DSM-IV. Am J Psychiatry 161:1231-1237.
– reference: Fernandez-Ruiz J, Hernandez M, Ramos JA (2010) Cannabinoid-dopamine interaction in the pathophysiology and treatment of CNS disorders. CNS Neurosci Ther 16:e72-e91.
– reference: Caille S, Alvarez-Jaimes L, Polis I, Stouffer DG, Parsons LH (2007) Specific alterations of extracellular endocannabinoid levels in the nucleus accumbens by ethanol, heroin, and cocaine self-administration. J Neurosci 27:3695-3702.
– reference: Herrero MJ, Domingo-Salvany A, Torrens M, Brugal MT (2008) Psychiatric comorbidity in young cocaine users: induced versus independent disorders. Addiction 103:284-293.
– reference: Siegmund SV (2010) Role of the endocannabinoid system in alcoholic liver disease. Dig Dis 28:751-755.
– reference: Editorial team (2010) The EMCDDA annual report 2010: the state of the drugs problem in Europe. Euro Surveill 15:19714.
– reference: Pavón FJ, Serrano A, Romero-Cuevas M, Alonso M, Rodríguez de Fonseca F (2010) Oleoylethanolamide: a new player in peripheral control of energy metabolism. Therapeutic implications. Drug Discov Today Dis Mech 7:e175-e183.
– reference: Potvin S, Kouassi E, Lipp O, Bouchard RH, Roy MA, Demers MF, Gendron A, Astarita G, Piomelli D, Stip E (2008) Endogenous cannabinoids in patients with schizophrenia and substance use disorder during quetiapine therapy. J Psychopharmacol 22:262-269.
– reference: Hill MN, Miller GE, Ho WS, Gorzalka BB, Hillard CJ (2008) Serum endocannabinoid content is altered in females with depressive disorders: a preliminary report. Pharmacopsychiatry 41:48-53.
– reference: Matias I, Gatta-Cherifi B, Tabarin A, Clark S, Leste-Lasserre T, Marsicano G, Piazza PV, Cota D (2012) Endocannabinoids measurement in human saliva as potential biomarker of obesity. PLoS ONE 7:e42399.
– reference: Ueda N, Tsuboi K, Uyama T (2010) Enzymological studies on the biosynthesis of N-acylethanolamines. Biochim Biophys Acta 1801:1274-1285.
– reference: Orio L, Pavon FJ, Blanco E, Serrano A, Araos P, Pedraz M, Rivera P, Calado M, Suarez J, de Fonseca FR (2013) Lipid transmitter signaling as a new target for treatment of cocaine addiction: new roles for acylethanolamides and lysophosphatidic acid. Curr Pharm Des [Epub ahead of print].
– reference: Razzouk D, Bordin IA, Jorge MR (2000) Comorbidity and global functioning (DSM-III-R Axis V) in a Brazilian sample of cocaine users. Subst Use Misuse 35:1307-1315.
– reference: De Vries TJ, Shaham Y, Homberg JR, Crombag H, Schuurman K, Dieben J, Vanderschuren LJ, Schoffelmeer AN (2001) A cannabinoid mechanism in relapse to cocaine seeking. Nat Med 7:1151-1154.
– reference: Rivera P, Luque-Rojas MJ, Pastor A, Blanco E, Pavon FJ, Serrano A, Crespillo A, Vida M, Grondona JM, Cifuentes M, Bermudez-Silva FJ, de la Torre R, de Fonseca FR, Suarez J (2013a) Diet-dependent modulation of hippocampal expression of endocannabinoid signaling-related proteins in cannabinoid antagonist-treated obese rats. Eur J Neurosci 37:105-117.
– reference: Fu J, Gaetani S, Oveisi F, Lo Verme J, Serrano A, Rodriguez De Fonseca F, Rosengarth A, Luecke H, Di Giacomo B, Tarzia G, Piomelli D (2003) Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-alpha. Nature 425:90-93.
– reference: Vergara-Moragues E, Gonzalez-Saiz F, Lozano OM, Betanzos Espinosa P, Fernandez Calderon F, Bilbao-Acebos I, Perez Garcia M, Verdejo Garcia A (2012) Psychiatric comorbidity in cocaine users treated in therapeutic community: substance-induced versus independent disorders. Psychiatry Res 200:734-741.
– reference: Ben-Shahar O, Sacramento AD, Miller BW, Webb SM, Wroten MG, Silva HE, Caruana AL, Gordon EJ, Ploense KL, Ditzhazy J, Kippin TE, Szumlinski KK (2013) Deficits in ventromedial prefrontal cortex group 1 metabotropic glutamate receptor function mediate resistance to extinction during protracted withdrawal from an extensive history of cocaine self-administration. J Neurosci 33:495-506a.
– reference: Rivera P, Miguens M, Coria SM, Rubio L, Higuera-Matas A, Bermudez-Silva FJ, de Fonseca FR, Suarez J, Ambrosio E (2013b) Cocaine self-administration differentially modulates the expression of endogenous cannabinoid system-related proteins in the hippocampus of Lewis vs. Fischer 344 rats. Int J Neuropsychopharmacol 16:1277-1293.
– reference: LoVerme J, La Rana G, Russo R, Calignano A, Piomelli D (2005) The search for the palmitoylethanolamide receptor. Life Sci 77:1685-1698.
– reference: Riddle EL, Fleckenstein AE, Hanson GR (2005) Role of monoamine transporters in mediating psychostimulant effects. AAPS J 7:E847-E851.
– reference: Ben-Shabat S, Fride E, Sheskin T, Tamiri T, Rhee MH, Vogel Z, Bisogno T, De Petrocellis L, Di Marzo V, Mechoulam R (1998) An entourage effect: inactive endogenous fatty acid glycerol esters enhance 2-arachidonoyl-glycerol cannabinoid activity. Eur J Pharmacol 353:23-31.
– reference: Rodriguez de Fonseca F, Del Arco I, Bermudez-Silva FJ, Bilbao A, Cippitelli A, Navarro M (2005) The endocannabinoid system: physiology and pharmacology. Alcohol Alcohol 40:2-14.
– reference: Sipe JC, Scott TM, Murray S, Harismendy O, Simon GM, Cravatt BF, Waalen J (2010) Biomarkers of endocannabinoid system activation in severe obesity. PLoS ONE 5:e8792.
– reference: Hansen HS (2010) Palmitoylethanolamide and other anandamide congeners. Proposed role in the diseased brain. Exp Neurol 224:48-55.
– reference: Hasin DS, Fenton MC, Beseler C, Park JY, Wall MM (2012) Analyses related to the development of DSM-5 criteria for substance use related disorders: 2. Proposed DSM-5 criteria for alcohol, cannabis, cocaine and heroin disorders in 663 substance abuse patients. Drug Alcohol Depend 122:28-37.
– reference: Wiskerke J, Pattij T, Schoffelmeer AN, De Vries TJ (2008) The role of CB1 receptors in psychostimulant addiction. Addict Biol 13:225-238.
– reference: Syed SK, Bui HH, Beavers LS, Farb TB, Ficorilli J, Chesterfield AK, Kuo MS, Bokvist K, Barrett DG, Efanov AM (2012) Regulation of GPR119 receptor activity with endocannabinoid-like lipids. Am J Physiol Endocrinol Metab 303:E1469-E1478.
– reference: Ferrer B, Bermudez-Silva FJ, Bilbao A, Alvarez-Jaimes L, Sanchez-Vera I, Giuffrida A, Serrano A, Baixeras E, Khaturia S, Navarro M, Parsons LH, Piomelli D, Rodriguez de Fonseca F (2007) Regulation of brain anandamide by acute administration of ethanol. Biochem J 404:97-104.
– reference: Feuerecker M, Hauer D, Gresset T, Lassas S, Kaufmann I, Vogeser M, Briegel J, Hornuss C, Chouker A, Schelling G (2012) Effect of an acute consumption of a moderate amount of ethanol on plasma endocannabinoid levels in humans. Alcohol Alcohol 47:226-232.
– reference: Gonzalez S, Cascio MG, Fernandez-Ruiz J, Fezza F, Di Marzo V, Ramos JA (2002) Changes in endocannabinoid contents in the brain of rats chronically exposed to nicotine, ethanol or cocaine. Brain Res 954:73-81.
– reference: De Marchi N, De Petrocellis L, Orlando P, Daniele F, Fezza F, Di Marzo V (2003) Endocannabinoid signalling in the blood of patients with schizophrenia. Lipids Health Dis 2:5.
– reference: Plaza-Zabala A, Berrendero F, Suarez J, Bermudez-Silva FJ, Fernandez-Espejo E, Serrano A, Pavon FJ, Parsons LH, De Fonseca FR, Maldonado R, Robledo P (2010) Effects of the endogenous PPAR-alpha agonist, oleoylethanolamide on MDMA-induced cognitive deficits in mice. Synapse 64:379-389.
– reference: Giuffrida A, Leweke FM, Gerth CW, Schreiber D, Koethe D, Faulhaber J, Klosterkotter J, Piomelli D (2004) Cerebrospinal anandamide levels are elevated in acute schizophrenia and are inversely correlated with psychotic symptoms. Neuropsychopharmacology 29:2108-2114.
– reference: Thomas MJ, Kalivas PW, Shaham Y (2008) Neuroplasticity in the mesolimbic dopamine system and cocaine addiction. Br J Pharmacol 154:327-342.
– reference: Quercioli A, Pataky Z, Vincenti G, Makoundou V, Di Marzo V, Montecucco F, Carballo S, Thomas A, Staub C, Steffens S, Seimbille Y, Golay A, Ratib O, Harsch E, Mach F, Schindler TH (2011) Elevated endocannabinoid plasma levels are associated with coronary circulatory dysfunction in obesity. Eur Heart J 32:1369-1378.
– reference: Koppel J, Bradshaw H, Goldberg TE, Khalili H, Marambaud P, Walker MJ, Pazos M, Gordon ML, Christen E, Davies P (2009) Endocannabinoids in Alzheimer's disease and their impact on normative cognitive performance: a case-control and cohort study. Lipids Health Dis 8:2.
– reference: Di Marzo V, Deutsch DG (1998) Biochemistry of the endogenous ligands of cannabinoid receptors. Neurobiol Dis 5:386-404.
– reference: Karila L, Petit A, Lowenstein W, Reynaud M (2012) Diagnosis and consequences of cocaine addiction. Curr Med Chem 19:5612-5618.
– reference: Kaufmann I, Hauer D, Huge V, Vogeser M, Campolongo P, Chouker A, Thiel M, Schelling G (2009) Enhanced anandamide plasma levels in patients with complex regional pain syndrome following traumatic injury: a preliminary report. Eur Surg Res 43:325-329.
– reference: Mascia P, Pistis M, Justinova Z, Panlilio LV, Luchicchi A, Lecca S, Scherma M, Fratta W, Fadda P, Barnes C, Redhi GH, Yasar S, Le Foll B, Tanda G, Piomelli D, Goldberg SR (2011) Blockade of nicotine reward and reinstatement by activation of alpha-type peroxisome proliferator-activated receptors. Biol Psychiatry 69:633-641.
– reference: Schwarz E, Whitfield P, Nahnsen S, Wang L, Major H, Leweke FM, Koethe D, Lio P, Bahn S (2011) Alterations of primary fatty acid amides in serum of patients with severe mental illness. Front Biosci (Elite Ed) 3:308-314.
– reference: Jean-Gilles L, Feng S, Tench CR, Chapman V, Kendall DA, Barrett DA, Constantinescu CS (2009) Plasma endocannabinoid levels in multiple sclerosis. J Neurol Sci 287:212-215.
– reference: Liu HS, Chefer S, Lu H, Guillem K, Rea W, Kurup P, Yang Y, Peoples L, Stein EA (2013) Dorsolateral caudate nucleus differentiates cocaine from natural reward-associated contextual cues. Proc Natl Acad Sci U S A 110:4093-4098.
– reference: Deschaux O, Vendruscolo LF, Schlosburg JE, Diaz-Aguilar L, Yuan CJ, Sobieraj JC, George O, Koob GF, Mandyam CD (2012) Hippocampal neurogenesis protects against cocaine-primed relapse. Addict Biol. doi:10.1111/adb.12019.
– reference: Giuffrida A, Parsons LH, Kerr TM, Rodriguez de Fonseca F, Navarro M, Piomelli D (1999) Dopamine activation of endogenous cannabinoid signaling in dorsal striatum. Nat Neurosci 2:358-363.
– reference: Morgello S, Holzer CE 3rd, Ryan E, Young C, Naseer M, Castellon SA, Frol AB, Atkinson JH, Gelman BB, Grant I, Singer EJ (2006) Interrater reliability of the Psychiatric Research Interview for Substance and Mental Disorders in an HIV-infected cohort: experience of the National NeuroAIDS Tissue Consortium. Int J Methods Psychiatr Res 15:131-138.
– reference: Robins LN, Wing J, Wittchen HU, Helzer JE, Babor TF, Burke J, Farmer A, Jablenski A, Pickens R, Regier DA, Sartorius N, Towle LH (1988) The Composite International Diagnostic Interview-an epidemiologic instrument suitable for use in conjunction with different diagnostic systems and in different cultures. Arch Gen Psychiatry 45:1069-1077.
– reference: Serrano A, Parsons LH (2011) Endocannabinoid influence in drug reinforcement, dependence and addiction-related behaviors. Pharmacol Ther 132:215-241.
– reference: Mangieri RA, Hong KI, Piomelli D, Sinha R (2009) An endocannabinoid signal associated with desire for alcohol is suppressed in recently abstinent alcoholics. Psychopharmacology (Berl) 205:63-72.
– volume: 32
  start-page: 1369
  year: 2011
  end-page: 1378
  article-title: Elevated endocannabinoid plasma levels are associated with coronary circulatory dysfunction in obesity
  publication-title: Eur Heart J
– volume: 77
  start-page: 1685
  year: 2005
  end-page: 1698
  article-title: The search for the palmitoylethanolamide receptor
  publication-title: Life Sci
– volume: 7
  start-page: E847
  year: 2005
  end-page: E851
  article-title: Role of monoamine transporters in mediating psychostimulant effects
  publication-title: AAPS J
– volume: 33
  start-page: 676
  year: 2008
  end-page: 685
  article-title: Anandamide and neutrophil function in patients with fibromyalgia
  publication-title: Psychoneuroendocrinology
– volume: 3
  start-page: 308
  year: 2011
  end-page: 314
  article-title: Alterations of primary fatty acid amides in serum of patients with severe mental illness
  publication-title: Front Biosci (Elite Ed)
– volume: 103
  start-page: 284
  year: 2008
  end-page: 293
  article-title: Psychiatric comorbidity in young cocaine users: induced versus independent disorders
  publication-title: Addiction
– volume: 954
  start-page: 73
  year: 2002
  end-page: 81
  article-title: Changes in endocannabinoid contents in the brain of rats chronically exposed to nicotine, ethanol or cocaine
  publication-title: Brain Res
– volume: 15
  start-page: 131
  year: 2006
  end-page: 138
  article-title: Interrater reliability of the Psychiatric Research Interview for Substance and Mental Disorders in an HIV‐infected cohort: experience of the National NeuroAIDS Tissue Consortium
  publication-title: Int J Methods Psychiatr Res
– volume: 41
  start-page: 48
  year: 2008
  end-page: 53
  article-title: Serum endocannabinoid content is altered in females with depressive disorders: a preliminary report
  publication-title: Pharmacopsychiatry
– volume: 132
  start-page: 215
  year: 2011
  end-page: 241
  article-title: Endocannabinoid influence in drug reinforcement, dependence and addiction‐related behaviors
  publication-title: Pharmacol Ther
– volume: 64
  start-page: 379
  year: 2010
  end-page: 389
  article-title: Effects of the endogenous PPAR‐alpha agonist, oleoylethanolamide on MDMA‐induced cognitive deficits in mice
  publication-title: Synapse
– volume: 110
  start-page: 4093
  year: 2013
  end-page: 4098
  article-title: Dorsolateral caudate nucleus differentiates cocaine from natural reward‐associated contextual cues
  publication-title: Proc Natl Acad Sci U S A
– year: 2013
  article-title: Lipid transmitter signaling as a new target for treatment of cocaine addiction: new roles for acylethanolamides and lysophosphatidic acid
  publication-title: Curr Pharm Des
– volume: 205
  start-page: 63
  year: 2009
  end-page: 72
  article-title: An endocannabinoid signal associated with desire for alcohol is suppressed in recently abstinent alcoholics
  publication-title: Psychopharmacology (Berl)
– year: 2012
  article-title: Hippocampal neurogenesis protects against cocaine‐primed relapse
  publication-title: Addict Biol
– volume: 404
  start-page: 97
  year: 2007
  end-page: 104
  article-title: Regulation of brain anandamide by acute administration of ethanol
  publication-title: Biochem J
– volume: 16
  start-page: e72
  year: 2010
  end-page: e91
  article-title: Cannabinoid‐dopamine interaction in the pathophysiology and treatment of CNS disorders
  publication-title: CNS Neurosci Ther
– volume: 30
  start-page: 1216
  year: 2005
  end-page: 1221
  article-title: Blood levels of the endocannabinoid anandamide are increased in anorexia nervosa and in binge‐eating disorder, but not in bulimia nervosa
  publication-title: Neuropsychopharmacology
– volume: 37
  start-page: 105
  year: 2013a
  end-page: 117
  article-title: Diet‐dependent modulation of hippocampal expression of endocannabinoid signaling‐related proteins in cannabinoid antagonist‐treated obese rats
  publication-title: Eur J Neurosci
– volume: 28
  start-page: 751
  year: 2010
  end-page: 755
  article-title: Role of the endocannabinoid system in alcoholic liver disease
  publication-title: Dig Dis
– volume: 7
  start-page: e175
  year: 2010
  end-page: e183
  article-title: Oleoylethanolamide: a new player in peripheral control of energy metabolism. Therapeutic implications
  publication-title: Drug Discov Today Dis Mech
– volume: 27
  start-page: 3695
  year: 2007
  end-page: 3702
  article-title: Specific alterations of extracellular endocannabinoid levels in the nucleus accumbens by ethanol, heroin, and cocaine self‐administration
  publication-title: J Neurosci
– volume: 45
  start-page: 1069
  year: 1988
  end-page: 1077
  article-title: The Composite International Diagnostic Interview—an epidemiologic instrument suitable for use in conjunction with different diagnostic systems and in different cultures
  publication-title: Arch Gen Psychiatry
– volume: 29
  start-page: 2108
  year: 2004
  end-page: 2114
  article-title: Cerebrospinal anandamide levels are elevated in acute schizophrenia and are inversely correlated with psychotic symptoms
  publication-title: Neuropsychopharmacology
– volume: 18
  start-page: 78
  year: 2013
  end-page: 87
  article-title: Oleoylethanolamide dose‐dependently attenuates cocaine‐induced behaviours through a PPARalpha receptor‐independent mechanism
  publication-title: Addict Biol
– volume: 161
  start-page: 1231
  year: 2004
  end-page: 1237
  article-title: Diagnosing comorbid psychiatric disorders in substance abusers: validity of the Spanish versions of the Psychiatric Research Interview for Substance and Mental Disorders and the Structured Clinical Interview for DSM‐IV
  publication-title: Am J Psychiatry
– volume: 7
  start-page: 1151
  year: 2001
  end-page: 1154
  article-title: A cannabinoid mechanism in relapse to cocaine seeking
  publication-title: Nat Med
– volume: 224
  start-page: 48
  year: 2010
  end-page: 55
  article-title: Palmitoylethanolamide and other anandamide congeners. Proposed role in the diseased brain
  publication-title: Exp Neurol
– volume: 19
  start-page: 5612
  year: 2012
  end-page: 5618
  article-title: Diagnosis and consequences of cocaine addiction
  publication-title: Curr Med Chem
– volume: 5
  start-page: 386
  year: 1998
  end-page: 404
  article-title: Biochemistry of the endogenous ligands of cannabinoid receptors
  publication-title: Neurobiol Dis
– volume: 7
  start-page: e42399
  year: 2012
  article-title: Endocannabinoids measurement in human saliva as potential biomarker of obesity
  publication-title: PLoS ONE
– volume: 69
  start-page: 633
  year: 2011
  end-page: 641
  article-title: Blockade of nicotine reward and reinstatement by activation of alpha‐type peroxisome proliferator‐activated receptors
  publication-title: Biol Psychiatry
– volume: 154
  start-page: 327
  year: 2008
  end-page: 342
  article-title: Neuroplasticity in the mesolimbic dopamine system and cocaine addiction
  publication-title: Br J Pharmacol
– volume: 33
  start-page: 495
  year: 2013
  end-page: 506a
  article-title: Deficits in ventromedial prefrontal cortex group 1 metabotropic glutamate receptor function mediate resistance to extinction during protracted withdrawal from an extensive history of cocaine self‐administration
  publication-title: J Neurosci
– volume: 353
  start-page: 23
  year: 1998
  end-page: 31
  article-title: An entourage effect: inactive endogenous fatty acid glycerol esters enhance 2‐arachidonoyl‐glycerol cannabinoid activity
  publication-title: Eur J Pharmacol
– volume: 287
  start-page: 212
  year: 2009
  end-page: 215
  article-title: Plasma endocannabinoid levels in multiple sclerosis
  publication-title: J Neurol Sci
– volume: 8
  start-page: 2
  year: 2009
  article-title: Endocannabinoids in Alzheimer's disease and their impact on normative cognitive performance: a case‐control and cohort study
  publication-title: Lipids Health Dis
– volume: 13
  start-page: 225
  year: 2008
  end-page: 238
  article-title: The role of CB1 receptors in psychostimulant addiction
  publication-title: Addict Biol
– volume: 3
  start-page: 85
  year: 2012
  article-title: Plasma endocannabinoid alterations in individuals with substance use disorder are dependent on the ‘mirror effect’ of schizophrenia
  publication-title: Front Psychiatry
– volume: 22
  start-page: 262
  year: 2008
  end-page: 269
  article-title: Endogenous cannabinoids in patients with schizophrenia and substance use disorder during quetiapine therapy
  publication-title: J Psychopharmacol
– volume: 15
  start-page: 19714
  year: 2010
  article-title: The EMCDDA annual report 2010: the state of the drugs problem in Europe
  publication-title: Euro Surveill
– volume: 43
  start-page: 325
  year: 2009
  end-page: 329
  article-title: Enhanced anandamide plasma levels in patients with complex regional pain syndrome following traumatic injury: a preliminary report
  publication-title: Eur Surg Res
– volume: 303
  start-page: E1469
  year: 2012
  end-page: E1478
  article-title: Regulation of GPR119 receptor activity with endocannabinoid‐like lipids
  publication-title: Am J Physiol Endocrinol Metab
– volume: 16
  start-page: 1277
  year: 2013b
  end-page: 1293
  article-title: Cocaine self‐administration differentially modulates the expression of endogenous cannabinoid system‐related proteins in the hippocampus of Lewis vs. Fischer 344 rats
  publication-title: Int J Neuropsychopharmacol
– volume: 35
  start-page: 1307
  year: 2000
  end-page: 1315
  article-title: Comorbidity and global functioning (DSM‐III‐R Axis V) in a Brazilian sample of cocaine users
  publication-title: Subst Use Misuse
– volume: 47
  start-page: 226
  year: 2012
  end-page: 232
  article-title: Effect of an acute consumption of a moderate amount of ethanol on plasma endocannabinoid levels in humans
  publication-title: Alcohol Alcohol
– volume: 122
  start-page: 28
  year: 2012
  end-page: 37
  article-title: Analyses related to the development of DSM‐5 criteria for substance use related disorders: 2. Proposed DSM‐5 criteria for alcohol, cannabis, cocaine and heroin disorders in 663 substance abuse patients
  publication-title: Drug Alcohol Depend
– volume: 425
  start-page: 90
  year: 2003
  end-page: 93
  article-title: Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR‐alpha
  publication-title: Nature
– volume: 1801
  start-page: 1274
  year: 2010
  end-page: 1285
  article-title: Enzymological studies on the biosynthesis of N‐acylethanolamines
  publication-title: Biochim Biophys Acta
– volume: 163
  start-page: 689
  year: 2006
  end-page: 696
  article-title: Diagnosis of comorbid psychiatric disorders in substance users assessed with the Psychiatric Research Interview for Substance and Mental Disorders for DSM‐IV
  publication-title: Am J Psychiatry
– volume: 40
  start-page: 2
  year: 2005
  end-page: 14
  article-title: The endocannabinoid system: physiology and pharmacology
  publication-title: Alcohol Alcohol
– volume: 102
  start-page: 1216
  year: 2008
  end-page: 1219
  article-title: Illicit stimulant use in a United States heart failure population presenting to the emergency department (from the Acute Decompensated Heart Failure National Registry Emergency Module)
  publication-title: Am J Cardiol
– volume: 200
  start-page: 734
  year: 2012
  end-page: 741
  article-title: Psychiatric comorbidity in cocaine users treated in therapeutic community: substance‐induced versus independent disorders
  publication-title: Psychiatry Res
– volume: 5
  start-page: e8792
  year: 2010
  article-title: Biomarkers of endocannabinoid system activation in severe obesity
  publication-title: PLoS ONE
– volume: 2
  start-page: 358
  year: 1999
  end-page: 363
  article-title: Dopamine activation of endogenous cannabinoid signaling in dorsal striatum
  publication-title: Nat Neurosci
– volume: 66
  start-page: 363
  year: 2002
  end-page: 376
  article-title: Cannabinoid receptor‐inactive N‐acylethanolamines and other fatty acid amides: metabolism and function
  publication-title: Prostaglandins Leukot Essent Fatty Acids
– volume: 191
  start-page: 55
  year: 2011
  end-page: 77
  article-title: Neuroactive steroids in affective disorders: target for novel antidepressant or anxiolytic drugs?
  publication-title: Neuroscience
– volume: 2
  start-page: 5
  year: 2003
  article-title: Endocannabinoid signalling in the blood of patients with schizophrenia
  publication-title: Lipids Health Dis
SSID ssj0012753
Score 2.226181
Snippet Cocaine is associated with serious health problems including psychiatric co‐morbidity. There is a need for the identification of biomarkers for the...
Cocaine is associated with serious health problems including psychiatric co-morbidity. There is a need for the identification of biomarkers for the...
SourceID proquest
pubmed
wiley
istex
SourceType Aggregation Database
Index Database
Publisher
StartPage 955
SubjectTerms Abuse
Addiction
Adult
Ambulatory Care
Analysis of Variance
Area Under Curve
Biomarkers - blood
Case-Control Studies
Chromatography, Liquid - methods
cocaine
Cocaine-Related Disorders - blood
Cocaine-Related Disorders - epidemiology
Cocaine-Related Disorders - rehabilitation
Comorbidity
dependence
Diagnosis, Dual (Psychiatry)
DSM-IV-TR
endocannabinoid
Endocannabinoids - blood
Endocannabinoids - chemistry
Ethanolamines - blood
Ethanolamines - chemistry
Fatty Acids, Monounsaturated - blood
Female
Glycerides - blood
Glycerides - chemistry
Humans
Interview, Psychological
Logistic Models
Male
Mental Disorders - blood
Mental Disorders - epidemiology
Patient Acceptance of Health Care
psychiatric co-morbidity
ROC Curve
Severity of Illness Index
Tandem Mass Spectrometry - methods
Title Evaluation of plasma-free endocannabinoids and their congeners in abstinent cocaine addicts seeking outpatient treatment: impact of psychiatric co-morbidity
URI https://api.istex.fr/ark:/67375/WNG-CQJ3FP1Q-W/fulltext.pdf
https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fadb.12107
https://www.ncbi.nlm.nih.gov/pubmed/24283982
https://www.proquest.com/docview/1468674840
https://www.proquest.com/docview/1462762175
https://www.proquest.com/docview/1492644840
Volume 18
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1fa9swEBdZ-rKXsf_Llg0NRhkUl_iP7HhvSdusBFZaaGnfjCzLxaS1h-OMsad9hH2EfbXtk-xOUuSkpKPbiwmSItvcz6c73e9OhLzzwCoGTyJ0Ah6Bg-KJwEnDnDluJL0s5r70h5ic_OkoPDwLphfsotP5tcJaWjTprvi2Ma_kf6QKbSBXzJL9B8naSaEBfoN84QoShuudZHxgS3Ur4jIYwtfcshfyWsodWWawWJUlBwe4KrL5kjBZ1Mg3v8Sa04oQy1P41EvkBYCC5Gh5ItEIiR5zKWeKGb1oTA3WlpyO2wltmqUlThcCZrHPcV3VaZEVzVr8eKRmxwc3VaDaUNYXjN2PfWtWi2Iuqp0pxwW8hSfX9MBjmdVV-995o3cfRngyctHGV654praEQYM1IBlA_epuh-ubtL9WQYN95ISeTgHdlaYtjB03HAw2a_UbKjpmbGW1j_VBMbcsJDxLsfyGPpd3vVi3HcRuHabLCu-PVdc9suWBJ-N1ydZovD-e2FCXp0ul2hcz5a-QbmbnBc8JP_qvm9ygda9KmUWnD8kD48_QkQbnI9KR5WPS10nf9Fxe5byWdJsuG6p69oT8bHFLq5xq3P7-_gMRS28ilgJiqUIstYilRUktYqlBLDWIpQaxtEUstYj9QDVe1X1bvMIccH-L1KfkbHJwunfomJNCnMJnaqOdcT4QoWCABely14-knwcyyl2WMcnADEujOMaQvusLGXlSpEGah4Jz15XBwH9GumVVyheERsINpAC7Os_jAMz_mPEs4F44HORpGGdBj2wrUSSfdTWYhNczJEdGLDk_-pjsnUz9ybF7kpz3SH8pq8TojDk62kM83icY9Mhb2w0aHcN0vJTVQo3xwEQBu_5vY2K1s4LzPNc4sA_kYQ3FeOj1yHsFDNux9PcBVomCVbIE58u7D31F7rffZZ90m3ohX4Nd3qRvDLL_AHz35sA
linkProvider EBSCOhost
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Evaluation+of+plasma%E2%80%90free+endocannabinoids+and+their+congeners+in+abstinent+cocaine+addicts+seeking+outpatient+treatment%3A+impact+of+psychiatric+co%E2%80%90morbidity&rft.jtitle=Addiction+biology&rft.au=Pav%C3%B3n%2C+Francisco+Javier&rft.au=Araos%2C+Pedro&rft.au=Pastor%2C+Antoni&rft.au=Calado%2C+Montserrat&rft.date=2013-11-01&rft.issn=1355-6215&rft.eissn=1369-1600&rft.volume=18&rft.issue=6&rft.spage=955&rft.epage=969&rft_id=info:doi/10.1111%2Fadb.12107&rft.externalDBID=10.1111%252Fadb.12107&rft.externalDocID=ADB12107
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1355-6215&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1355-6215&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1355-6215&client=summon